Similar Papers

Paper Title
Journal
Date
Author
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon ... Benjamin Besse
Journal of Thoracic Oncology | VOL. 14
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
23 Apr 2019
238 Meta-analysis on the incidence of hyperprogressive disease during immune checkpoint inhibitor therapy
Seung Pyo Hong ... Young Kwang Chae
Journal for ImmunoTherapy of Cancer | VOL. 9
Seung Pyo Hong, et. al.Seung Pyo Hong ... Young Kwang Chae
01 Nov 2021
Abstract 3300: Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
Dan Zhao ... Erminia Massarelli
Cancer Research | VOL. 80
Dan Zhao, et. al.Dan Zhao ... Erminia Massarelli
13 Aug 2020
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer
Yunfang Yu ... Dagui Lin
JAMA Network Open | VOL. 2
Yunfang Yu, et. al.Yunfang Yu ... Dagui Lin
10 Jul 2019
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
A Perspective on the MARS2 Trial
Eric Lim ... Harvey Pass
Journal of Thoracic Oncology | VOL. -
Eric Lim, et. al.Eric Lim ... Harvey Pass
01 Jan 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
Afshin Dowlati ... Saiama N Waqar
Journal of Thoracic Oncology | VOL. -
Afshin Dowlati, et. al.Afshin Dowlati ... Saiama N Waqar
01 Jan 2025
Editorial Board
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.